XON-7 is under clinical development by Xenothera and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how XON-7’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
XON-7 overview
XON-7 is under development for the treatment of solid tumors including non-small cell lung (NSCL), pancreas, liver, colon, prostate, several lymphomas, gastro-esophageal adenocarcinoma, metastatic colorectal cancer, pancreatic cancer, sarcoma, triple-negative breast cancer, or metastatic ovarian cancer. and hematological tumor. It is a polyclonal antibody developed based on Xenothera technology platform. It is administered through intravenous route.
Xenothera overview
Xenothera, is a xenotherapy platform with embedded technology that renovates immunological treatments. The company is headquartered in France.
For a complete picture of XON-7’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
